Search Here

To improve their pandemic preparedness, one of the world's leading French pharmaceutical companies, Sanofi has invested in a $595 million vaccine facility in Singapore.

The Modulus facility is designed to be highly flexible, able to switch between producing different vaccines or treatments within days, unlike traditional plants that take months to adjust. Sanofi's Modulus can also manufacture up to four different vaccines or biopharmaceuticals at once, making it a versatile hub for global health needs.

CNBC reported that the Singapore site is one of two evolutive vaccine facilities that the company will build worldwide through its five-year, $948 million investment. Sanofi will also construct the other EVF in Neuville-sur-Saône, France. Executives have emphasized that the facility will come in handy for the company's quick response to future health crises, such as pandemics.

For Sanofi, in case a pandemic emerges, the resources can be diverted for immediate vaccine or treatment requirements.

By mid-2026, the facility will be in full operation and will be expected to create approximately 200 skilled jobs in Singapore, from bioprocess engineers and automation specialists to data analysts.

Singapore as a Global Biomedical Hub

According to NBC New York, Singapore's good reputation as a biomedical hub, along with its good business environment, made this an attractive place for this investment.

International biomedical investments are now being focused on by Singapore, a country that is now gaining much interest in the global healthcare industry. This new vaccine facility now joins a list of highly-profiled investments within the country, including the $256 million plant expansion earlier this year for Novartis. Such major pharmaceutical companies as AstraZeneca and Pfizer also picked Singapore as a location for their manufacturing operations, adding to its status as an essential hub for biopharmaceuticals.